This post has been archived and contains information that may be out of date.
The Centers for Medicare & Medicaid Services (CMS) has increased the Medicare payment rate for the administration of monoclonal antibodies for the treatment of beneficiaries with COVID-19.
The payment rate increase is effective May 6. In addition, CMS has established a higher reimbursement rate for monoclonal antibody administration performed in the beneficiary’s permanent residence or temporary lodging. CMS notes that it is establishing this higher rate in recognition of the increased costs associated with the one-on-one nature of this care model.
Additional information is available on the CMS Monoclonal Antibody COVID-19 Infusion website. Coding and billing information may also be accessed on the CMS website.